Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer

OBJECTIVE. To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS. Postme...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartzberg, Lee S., Franco, Sandra X., Florance, Allison, O'Rourke, Lisa, Maltzman, Julie, Johnston, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2010
Materias:
Academia–Pharma Intersect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227947/
https://www.ncbi.nlm.nih.gov/pubmed/20156908
http://dx.doi.org/10.1634/theoncologist.2009-0240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227947/
https://www.ncbi.nlm.nih.gov/pubmed/20156908
http://dx.doi.org/10.1634/theoncologist.2009-0240

Ejemplares similares